HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Incidence of exacerbations in the first 90 days of treatment with recombinant human interferon beta-1b in patients with relapsing-remitting multiple sclerosis.

Abstract
Interferon beta-1b (IFNbeta-1b) is effective in reducing the frequency of exacerbations in patients with relapsing-remitting multiple sclerosis (RRMS). Recently, a study suggested that treatment with IFNbeta-1b may place MS patients at risk of exacerbations by increasing interferon-gamma (IFNgamma)-secreting cells in the blood early after onset of treatment. We conducted a retrospective study in 192 RRMS patients treated with IFNbeta-1b. We did not observe an increase in the frequency of exacerbations early after the onset of treatment and suggest that the IFNgamma-secreting cell surge linked to the onset of treatment with IFNbeta-1b may not be clinically significant.
AuthorsO A Khan, J R Hebel
JournalAnnals of neurology (Ann Neurol) Vol. 44 Issue 1 Pg. 138-9 (Jul 1998) ISSN: 0364-5134 [Print] UNITED STATES
PMID9667604 (Publication Type: Journal Article)
Chemical References
  • Glucocorticoids
  • Neuroprotective Agents
  • Recombinant Proteins
  • Interferon beta-1b
  • Interferon-beta
  • Prednisone
  • Methylprednisolone
  • Interferon beta-1a
Topics
  • Administration, Oral
  • Adult
  • Case-Control Studies
  • Female
  • Glucocorticoids (administration & dosage)
  • Humans
  • Incidence
  • Injections, Intravenous
  • Interferon beta-1a
  • Interferon beta-1b
  • Interferon-beta (adverse effects, therapeutic use)
  • Male
  • Methylprednisolone (administration & dosage)
  • Middle Aged
  • Multiple Sclerosis (therapy)
  • Nervous System Diseases (epidemiology, etiology, prevention & control)
  • Neuroprotective Agents (administration & dosage)
  • Prednisone (administration & dosage)
  • Recombinant Proteins (adverse effects, therapeutic use)
  • Recurrence
  • Retrospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: